Stock Track | Pharming Group Soars 9.51% Pre-Market on Strong Q2 Results, Raised Guidance

Stock Track07-31

Shares of Pharming Group N.V. (PHAR) surged 9.51% in pre-market trading on Thursday following the company's announcement of better-than-expected second-quarter results and raised full-year guidance. The biotech firm, which specializes in rare disease treatments, reported significant growth in its commercial portfolio and pipeline advancements.

Pharming's second-quarter earnings per share came in at $0.06, considerably outperforming the analyst consensus estimate of -$0.03. This marks a substantial improvement from the $0.00 reported in the same quarter last year. Total revenues for the quarter reached $93.2 million, up 25.8% year-over-year and exceeding analyst expectations of $82.63 million. The company's flagship product, RUCONEST, saw a 28% increase in revenue to $80.4 million, while Joenja revenue grew 15% to $12.8 million.

Buoyed by the strong performance, Pharming raised its full-year 2025 revenue guidance to a range of $335 million to $350 million, up from the previous guidance of $325 million to $340 million. The company also reported progress in its pipeline, including advancements in leniolisib for additional primary immunodeficiencies and KL1333 for mitochondrial diseases. CEO Fabrice Chouraqui expressed confidence in the company's long-term strategy, citing the strength of their commercial portfolio and advancing pipeline targeting significant, underserved markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153188425?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153188425","market":"us","top_or_hot":-1,"title":"Stock Track | Pharming Group Soars 9.51% Pre-Market on Strong Q2 Results, Raised Guidance","media":"Stock Track","content":"<p>Shares of Pharming Group N.V. (PHAR) surged 9.51% in pre-market trading on Thursday following the company's announcement of better-than-expected second-quarter results and raised full-year guidance. The biotech firm, which specializes in rare disease treatments, reported significant growth in its commercial portfolio and pipeline advancements.</p>\n\n<p>Pharming's second-quarter earnings per share came in at $0.06, considerably outperforming the analyst consensus estimate of -$0.03. This marks a substantial improvement from the $0.00 reported in the same quarter last year. Total revenues for the quarter reached $93.2 million, up 25.8% year-over-year and exceeding analyst expectations of $82.63 million. The company's flagship product, RUCONEST, saw a 28% increase in revenue to $80.4 million, while Joenja revenue grew 15% to $12.8 million.</p>\n\n<p>Buoyed by the strong performance, Pharming raised its full-year 2025 revenue guidance to a range of $335 million to $350 million, up from the previous guidance of $325 million to $340 million. The company also reported progress in its pipeline, including advancements in leniolisib for additional primary immunodeficiencies and KL1333 for mitochondrial diseases. CEO Fabrice Chouraqui expressed confidence in the company's long-term strategy, citing the strength of their commercial portfolio and advancing pipeline targeting significant, underserved markets.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Pharming Group Soars 9.51% Pre-Market on Strong Q2 Results, Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Pharming Group Soars 9.51% Pre-Market on Strong Q2 Results, Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-07-31 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Pharming Group N.V. (PHAR) surged 9.51% in pre-market trading on Thursday following the company's announcement of better-than-expected second-quarter results and raised full-year guidance. The biotech firm, which specializes in rare disease treatments, reported significant growth in its commercial portfolio and pipeline advancements.</p>\n\n<p>Pharming's second-quarter earnings per share came in at $0.06, considerably outperforming the analyst consensus estimate of -$0.03. This marks a substantial improvement from the $0.00 reported in the same quarter last year. Total revenues for the quarter reached $93.2 million, up 25.8% year-over-year and exceeding analyst expectations of $82.63 million. The company's flagship product, RUCONEST, saw a 28% increase in revenue to $80.4 million, while Joenja revenue grew 15% to $12.8 million.</p>\n\n<p>Buoyed by the strong performance, Pharming raised its full-year 2025 revenue guidance to a range of $335 million to $350 million, up from the previous guidance of $325 million to $340 million. The company also reported progress in its pipeline, including advancements in leniolisib for additional primary immunodeficiencies and KL1333 for mitochondrial diseases. CEO Fabrice Chouraqui expressed confidence in the company's long-term strategy, citing the strength of their commercial portfolio and advancing pipeline targeting significant, underserved markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHAR","symbol_name":"Pharming Group N.V.","start_time":0,"source_url":"","article_id":"1153188425","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153188425","pubTimestamp":1753968537,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Pharming Group N.V. (PHAR) surged 9.51% in pre-market trading on Thursday following the company's announcement of better-than-expected second-quarter results and raised full-year guidance....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHAR":"Pharming Group N.V."},"translate_title":"个股追踪|Pharming Group盘前飙升9.51%，Q2业绩强劲，指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAR":1},"content_text":"Shares of Pharming Group N.V. (PHAR) surged 9.51% in pre-market trading on Thursday following the company's announcement of better-than-expected second-quarter results and raised full-year guidance. The biotech firm, which specializes in rare disease treatments, reported significant growth in its commercial portfolio and pipeline advancements.\nPharming's second-quarter earnings per share came in at $0.06, considerably outperforming the analyst consensus estimate of -$0.03. This marks a substantial improvement from the $0.00 reported in the same quarter last year. Total revenues for the quarter reached $93.2 million, up 25.8% year-over-year and exceeding analyst expectations of $82.63 million. The company's flagship product, RUCONEST, saw a 28% increase in revenue to $80.4 million, while Joenja revenue grew 15% to $12.8 million.\nBuoyed by the strong performance, Pharming raised its full-year 2025 revenue guidance to a range of $335 million to $350 million, up from the previous guidance of $325 million to $340 million. The company also reported progress in its pipeline, including advancements in leniolisib for additional primary immunodeficiencies and KL1333 for mitochondrial diseases. CEO Fabrice Chouraqui expressed confidence in the company's long-term strategy, citing the strength of their commercial portfolio and advancing pipeline targeting significant, underserved markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153188425","isCrawlerRequest":true}